Hand-out
Press Releases
Accent Therapeutics Presents Data Supporting Therapeutic Potential of First-in-Class DHX9 Inhibitor, ATX-559, and Novel KIF18A Inhibitor, ATX-295, at the AACR Annual Meeting 2025
ATX-559, a first-in-class oral DHX9 inhibitor, shown to induce potent and selective tumor growth inhibition in preclinical models of cancers with high genomic instability and replication stress
